RCUS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RCUS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Arcus Biosciences's quarterly gross PPE declined from Jun. 2024 ($49.0 Mil) to Sep. 2024 ($48.0 Mil) but then increased from Sep. 2024 ($48.0 Mil) to Dec. 2024 ($88.0 Mil).
Arcus Biosciences's annual gross PPE increased from Dec. 2022 ($58.0 Mil) to Dec. 2023 ($82.0 Mil) and increased from Dec. 2023 ($82.0 Mil) to Dec. 2024 ($88.0 Mil).
The historical data trend for Arcus Biosciences's Gross Property, Plant and Equipment can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcus Biosciences Annual Data | |||||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||||||
Gross Property, Plant and Equipment | Get a 7-Day Free Trial |
![]() |
37.88 | 50.00 | 58.00 | 82.00 | 88.00 |
Arcus Biosciences Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Gross Property, Plant and Equipment | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
82.00 | 51.00 | 49.00 | 48.00 | 88.00 |
Property, Plant and Equipment (PPE) are the fixed assets of the company. Fixed assets are also known as non-current assets.
Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.
Some of the most common parts of property, plant, and equipment are:
Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:
There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.
The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.
For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.
All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.
The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.
Arcus Biosciences (NYSE:RCUS) Gross Property, Plant and Equipment Explanation
A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.
Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.
Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.
Thank you for viewing the detailed overview of Arcus Biosciences's Gross Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.
Terry J Rosen | director, 10 percent owner, officer: Chief Executive Officer | C/O TULARK INC, TWO CORP DRIVE S, SAN FRANCISCO CA 94080 |
Yasunori Kaneko | director, 10 percent owner | 509 ROEHAMPTON, HILLS BOROUGH CA 94010 |
Gilead Sciences Inc | 10 percent owner | 333 LAKESIDE DR, FOSTER CITY CA 94404 |
Alexander Azoy | officer: Chief Accounting Officer | 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362 |
Jennifer Jarrett | officer: See Remarks | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Juan C. Jaen | director, 10 percent owner, officer: President | 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043 |
Goeltz Ii Robert C. | officer: Chief Financial Officer | 343 OYSTER POINT BLVD, SUITE 100, SOUTH SAN FRANCISCO CA 94080 |
Carolyn C. Tang | officer: General Counsel | 3928 POINT EDEN WAY, HAYWARD CA 94545 |
Dimitry Sa Nuyten | officer: Chief Medical Officer | 740 HEINZ AVENUE, C/O ADURO BIOTECH, INC., BERKELEY CA 94710 |
Linda Slanec Higgins | director | 3610 LOUIS RD., PALO ALTO CA 94303 |
Nicole Lambert | director | 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116 |
William Grossman | officer: Chief Medical Officer | C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
Kathryn E Falberg | director | C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Michael Quigley | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Andrew J Perlman | director | 618 MIRADA AVE, STANFORD CA 94305 |
From GuruFocus
By GuruFocus News • 02-25-2025
By Business Wire • 01-24-2025
By GuruFocus News • 02-26-2025
By Business Wire • 02-11-2025
By GuruFocus News • 02-16-2025
By GuruFocus News • 02-25-2025
By GuruFocus News • 02-10-2025
By Business Wire • 02-18-2025
By Business Wire • 02-25-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.